Search Result

Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma, NCCN clinical practice guidelines in oncology – Pancreatic Adenocarcinoma

https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

NCCN Guidelines Pancreatic Adenocarcinoma

NCCN Guidelines Pancreatic Adenocarcinoma, NCCN clinical practice guidelines in oncology – Pancreatic Adenocarcinoma

https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

Treatment by Cancer Type

Version: 2.2025 Ampullary Adenocarcinoma, Cancer Version: 2.2025 Pancreatic Adenocarcinoma Version: 2.2025 Pediatric Acute, Small Bowel Adenocarcinoma Version: 3.2025

https://www.nccn.org/guidelines/category_1

NCCN Guidelines Panels

Pancreatic Adenocarcinoma Panel, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel

https://www.nccn.org/education-research/continuing-education-(ce)/nccn-guidelines-in-practice/nccn-guidelines-panels

Guidelines for Patients

for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancers Version: 2025, Pancreatic Cancer Version: 2025, Adenocarcinoma Version: 2024 Small Cell Lung

https://www.nccn.org/guidelines/patients

( Small Bowel Adenocarcinoma ) Date: 2025-01-14 Transparency Panel Disclosures/Attendance, Transparency Panel Disclosures/Attendance Version: 1.2025 ( Small Bowel Adenocarcinoma, Transparency Panel Disclosures/Attendance Version: 4.2024 ( Small Bowel Adenocarcinoma, Version: 3.2024 ( Small Bowel Adenocarcinoma ) Date: 2024-04-17 Transparency Panel, Transparency Panel Disclosures/Attendance Version: 2.2024 ( Small Bowel Adenocarcinoma

https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations

Guidelines With Evidence Blocks

/Primary Peritoneal Cancer Version 2.2025 Pancreatic Adenocarcinoma Version 2.2025, Leukemia Version 2.2025 Acute Myeloid Leukemia Version 2.2025 Ampullary Adenocarcinoma, Version 2.2025 Small Bowel Adenocarcinoma Version 3.2025 Small Cell Lung Cancer

https://www.nccn.org/guidelines/guidelines-with-evidence-blocks

Framework for Resource Stratification Of NCCN Guidelines

Version 4.2024 NCCN Guidelines Version 7.2025 Pancreatic Adenocarcinoma Basic

https://www.nccn.org/global/what-we-do/nccn-framework-for-resource-stratification-of-nccn-guidelines

International Adaptations

Palliative Care Version 2.2021 Pancreatic Adenocarcinoma Version 2.2022, Assessment: Breast, Ovarian, Pancreatic, and Prostate Version 2.2025 (English) Hairy Cell

https://www.nccn.org/global/what-we-do/international-adaptations

Permission to Cite or Use NCCN Content

Peritoneal Cancer Palliative Care Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia, /Fallopian Tube Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute, Palliative Care Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive, /Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric, Ampullary Adenocarcinoma Anal Carcinoma Antiemesis Basal Cell Skin Cancer B-Cell Lymphomas Biliary

https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-content

Imaging AUC Compendium Reviewer Acknowledgement

Cancer Center at the University of Pennsylvania Pancreatic Adenocarcinoma, reviewed in 2024 for contributing their time and expertise: Ampullary Adenocarcinoma, High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Tuya

https://www.nccn.org/compendia-templates/compendia/imaging-appropriate-use-criteria-nccn-imaging-auc/imaging-auc-compendium-reviewer-acknowledgement

Biomarkers Compendium Reviewer Acknowledgment

Ardeshir Hakam, MD Moffitt Cancer Center Pancreatic Adenocarcinoma, Adenocarcinoma Elena Gabriela G. Chiorean, MD Fred, Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Adenocarcinoma Kristen K. Ciombor, MD

https://www.nccn.org/compendia-templates/compendia/biomarkers-compendium/biomarkers-compendium-reviewer-acknowledgment

ORP Grant History

in Patients with Advanced Pancreatic Cancer Renuka Iyer, MD Roswell Park Comprehensive Cancer Center Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic, Rate Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas Daniel, ) Genotype-Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic, Junction Adenocarcinoma Lakshmi Pendyala, PhD Roswell Park Comprehensive Cancer Center Gene Expression

https://www.nccn.org/education-research/nccn-oncology-research-program/orp-grant-history

Radiation Therapy Compendium Reviewer Acknowledgement

Pancreatic Adenocarcinoma Brian Czito, MD, Cancer Center Ampullary Adenocarcinoma Brian Czito, MD

https://www.nccn.org/compendia-templates/compendia/radiation-therapycompendium/radiation-therapy-compendium-reviewer-acknowledgement

Drugs and Biologics Reviewer Acknowledgement

, MD Johns Hopkins Kimmel Cancer Center Pancreatic Adenocarcinoma, University of Colorado Cancer Center Ampullary Adenocarcinoma, Cancer Center Small Bowel Adenocarcinoma Al B. Benson III, MD

https://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia/drugs-and-biologics-reviewer-acknowledgement

Resume Screening

Myeloid Leukemia Ampullary Adenocarcinoma Anal Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas, Cancer Occult Primary Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive Mature B-Cell Lymphomas, Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung, , Ovarian, Pancreatic, and Prostate Genetic/Familial High-Risk Assessment: Colorectal, Endometrial

https://www.nccn.org/covid-19/resume-screening

Chemotherapy Order Templates Reviewer Acknowledgement

Adenocarcinoma Kelsey A. Klute, MD Fred & Pamela, Huntsman Cancer Institute at the University of Utah Pancreatic Adenocarcinoma Efrat Dotan, MD Abramson Cancer Center, Cancer Center Small Bowel Adenocarcinoma Courtney C. Cavalieri

https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagement

Guidelines Panels

Panel Pancreatic Adenocarcinoma Panel, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel

https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panels

Submission Request Form

Peritoneal Cancer - 1.2025 Palliative Care - 2.2025 Pancreatic Adenocarcinoma - 2.2025 Pediatric Acute, Ampullary Adenocarcinoma - 2.2025 Anal Carcinoma - 3.2025 Antiemesis - 2.2025 Basal Cell Skin Cancer, - 1.2025 Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate - 3.2025, Bowel Adenocarcinoma - 3.2025 Small Cell Lung Cancer - 4.2025 Smoking Cessation - 1.2025 Soft Tissue

https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-form

HIT

Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive, Leukemia Acute Myeloid Leukemia Ampullary Adenocarcinoma Anal Carcinoma Basal Cell Skin Cancer, Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma, Assessment: Breast, Ovarian, Pancreatic, and Prostate Genetic/Familial High-Risk Assessment, Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancers Graft-Versus-Host Disease

https://www.nccn.org/redirects/hit